Literature DB >> 22379062

Tick-borne encephalitis virus-neutralizing antibodies in different immunoglobulin preparations.

Philip O Rabel1, Christina B Planitzer, Maria R Farcet, Thomas R Kreil.   

Abstract

Patients with primary immunodeficiency (PIDs) depend on the presence of a variety of antibody specificities in intravenous immunoglobulin (IVIG). Using the tick-borne encephalitis virus (TBEV), geographic variability in IVIG antibody content was shown. Care should therefore be exercised when treating PIDs in a given geography, as only locally sourced plasma contains the antibody specificities against the circulating pathogens in the given locality.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22379062      PMCID： PMC3318267          DOI： 10.1128/CVI.05705-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  34 in total

1.  Tick borne encephalitis TBE--vaccination in non-endemic countries.

Authors:  Ursula Wiedermann
Journal:  Travel Med Infect Dis       Date:  2010-06-25       Impact factor: 6.211

Review 2.  Tick-borne encephalitis: pathogenesis and clinical implications.

Authors:  Daniel Růžek; Gerhard Dobler; Oliver Donoso Mantke
Journal:  Travel Med Infect Dis       Date:  2010-07-21       Impact factor: 6.211

3.  Neutralization of different echovirus serotypes by individual lots of intravenous immunoglobulin.

Authors:  Christina B Planitzer; Maria R Farcet; Richard I Schiff; Hans D Ochs; Thomas R Kreil
Journal:  J Med Virol       Date:  2011-02       Impact factor: 2.327

4.  Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile virus.

Authors:  Yvonne Hofmeister; Christina B Planitzer; Maria R Farcet; Wolfgang Teschner; H Arno Butterweck; Alfred Weber; Georg W Holzer; Thomas R Kreil
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

5.  Vaccination against tick-borne encephalitis virus tests specific IgG production ability in patients under immunoglobulin substitution therapy.

Authors:  Markus G Seidel; Eva Grohmann; Kambis Sadeghi; Arnold Pollak; Andreas Heitger; Elisabeth Förster-Waldl
Journal:  Vaccine       Date:  2010-07-23       Impact factor: 3.641

6.  Hepatitis A virus antibodies in immunoglobulin preparations.

Authors:  Maria R Farcet; Christina B Planitzer; Oliver Stein; Jens Modrof; Thomas R Kreil
Journal:  J Allergy Clin Immunol       Date:  2009-12-04       Impact factor: 10.793

7.  Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype.

Authors:  W W Shanaka I Rodrigo; Olivia K T Block; Christopher Lane; Soila Sukupolvi-Petty; Ana P Goncalvez; Syd Johnson; Michael S Diamond; Ching-Juh Lai; Robert C Rose; Xia Jin; Jacob J Schlesinger
Journal:  Virology       Date:  2009-10-14       Impact factor: 3.616

8.  Characterization of neutralizing antibodies to Far Eastern of tick-borne encephalitis virus subtype and the antibody avidity for four tick-borne encephalitis vaccines in human.

Authors:  Galina N Leonova; Elena V Pavlenko
Journal:  Vaccine       Date:  2009-03-03       Impact factor: 3.641

9.  West Nile virus infection in plasma of blood and plasma donors, United States.

Authors:  Christina B Planitzer; Jens Modrof; Mei-ying W Yu; Thomas R Kreil
Journal:  Emerg Infect Dis       Date:  2009-10       Impact factor: 6.883

10.  Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection.

Authors:  David Ben-Nathan; Orly Gershoni-Yahalom; Itzchak Samina; Yevgeny Khinich; Israel Nur; Orgad Laub; Ahuva Gottreich; Michael Simanov; Angel Porgador; Bracha Rager-Zisman; Nadav Orr
Journal:  BMC Infect Dis       Date:  2009-02-17       Impact factor: 3.090
View more
  7 in total

1.  Characterization of antibody specificities associated with preeclampsia.

Authors:  Serra E Elliott; Nicholas F Parchim; Chen Liu; Yang Xia; Rodney E Kellems; Alex R Soffici; Patrick S Daugherty
Journal:  Hypertension       Date:  2014-01-20       Impact factor: 10.190

2.  Two Cases of Severe Tick-Borne Encephalitis in Rituximab-Treated Patients in Germany: Implications for Diagnosis and Prevention.

Authors:  Philipp A Steininger; Tobias Bobinger; Wenke Dietrich; De-Hyung Lee; Michael Knott; Christian Bogdan; Klaus Korn; Roland Lang
Journal:  Open Forum Infect Dis       Date:  2017-09-26       Impact factor: 3.835

3.  Detection of impaired IgG antibody formation facilitates the decision on early immunoglobulin replacement in hypogammaglobulinemic patients.

Authors:  Hermann M Wolf; Vojtech Thon; Jiri Litzman; Martha M Eibl
Journal:  Front Immunol       Date:  2015-02-02       Impact factor: 7.561

4.  May early intervention with high dose intravenous immunoglobulin pose a potentially successful treatment for severe cases of tick-borne encephalitis?

Authors:  Daniel Růžek; Gerhard Dobler; Hans Helmut Niller
Journal:  BMC Infect Dis       Date:  2013-07-03       Impact factor: 3.090

5.  Analysis of specific IgG titers against tick-borne encephalitis in patients with primary antibody deficiency under immunoglobulin substitution therapy: impact of plasma donor origin.

Authors:  Sigune Goldacker; Torsten Witte; Daniela Huzly; Michael Schlesier; Hans-Hartmut Peter; Klaus Warnatz
Journal:  Front Immunol       Date:  2015-01-05       Impact factor: 7.561

6.  Characterization of antibodies in human immunoglobulin products from different regions worldwide.

Authors:  Alexandra Serra; Núria Marzo; Berta Pons; Pau Maduell; Maite López; Salvador Grancha
Journal:  Int J Infect Dis       Date:  2021-01-29       Impact factor: 3.623

7.  Affinity-purified respiratory syncytial virus antibodies from intravenous immunoglobulin exert potent antibody-dependent cellular cytotoxicity.

Authors:  Nimesh Gupta; Jerome LeGoff; Soulaima Chamat; Severine Mercier-Delarue; Olivier Touzelet; Ultan F Power; Michel D Kazatchkine; Francois Simon; Sebastien Lacroix-Desmazes; Jagadeesh Bayry; Srinivas V Kaveri
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.